Patent Case Watch

Patent opinions from the Eastern District of Texas and the U.S. Court of Appeals for the Federal Circuit

Fed. Cir.

Shire LLC v. Amneal Pharmaceuticals, LLC, No. 14-1736 (Fed. Cir. Sept. 24, 2015)

Affirmed in Part
Invalidity (§ 102/§ 103) Induced Infringement Contentions
Court
U.S. Court of Appeals for the Federal Circuit
Case No.
No. 14-1736
Also Docketed
No. 14-1737, No. 14-1738, No. 14-1739, No. 14-1740, No. 14-1741 (consolidated; same document)
Decided
September 24, 2015
Judge
Linn, J.
Document
Precedential Opinion
Length
16 pages

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

In this consolidated Hatch-Waxman Act litigation, Amneal Pharmaceuticals, LLC, Actavis Elizabeth LLC , Actavis LLC, Mylan Inc. , Mylan Pharmaceuticals Inc., Roxane Laboratories, Inc., Sandoz Inc. (collectively the “ANDA defendants”) and Johnson Matthey Pharmaceut i- cal Materials (“Johnson Ma tthey”) (collectively, “defen d- ants”) appeal the district court’s decision in Shire, LLC v. Amneal Pharmaceuticals, LLC , No. 11 -3781, 2014 WL 2861430 ( D.N.J. June 23, 2014) (“Op.”), granting Shire LLC, Shire Development Inc.

Download Opinion (PDF)

Source: govinfo.gov USCOURTS collection · retrieved July 23, 2026 · Report an error

Other documents in this case